Rimonabant Meta-Analysis Reveals Increased Risk Of Psychiatric Events – The Lancet
This article was originally published in The Pink Sheet Daily
Executive Summary
Study introduces nothing new about the obesity drug that has not been discussed with regulatory authorities, Sanofi-Aventis responds to “The Pink Sheet” DAILY.